Lung squamous cell carcinoma (lung SCC) is a common type of lung cancer, but its mechanism of pathogenesis is unclear. The aim of this study was to identify key transcription factors in lung SCC and elucidate its mechanism.
Background
Lung cancer is the most frequent cause of cancer death and an estimated 1.8 million new cases occurred in 2012 worldwide, accounting for about 13% of total cancer diagnosis [1] . Lung cancer is the leading cancer site in males, including 17% of the total new cancer cases and 23% of the total cancer deaths in 2008 worldwide [2] . Tobacco use is the major risk factor for lung cancer [3] .
Lung cancer is classified as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) according to histopathology appearance. NSCLC accounts for 80% of lung cancers. NSCLC is divided into three major histological subtypes, including adenocarcinoma (AC), squamous cell carcinoma (SCC), and large cell carcinoma (LCC) [4] . Lung SCC is the second most frequent type of NSCLC after lung AC [5] . In recent years, molecular target therapies for lung AC, including tyrosine kinase inhibitor (gefitinib/erlotinib) against EGFR-sensitive mutants [6, 7] , crizotinib against ALK fusion [8] , and bevacizumab against VEGF over-expression [9] , have shown remarkable therapeutic efficacy. However, there is no currently approved molecular target therapy for treatment of lung SCC other than chemotherapy [10] [11] [12] .
Currently, the pathogenesis mechanism of lung SCC remains unclear. It is reported that dysregulated genes, dysregulated miRNAs, and aberrantly methylated genes are associated with the progression of lung SCC. Hugl-l functions as a tumor suppressor, and the reduced expression of Hugl-1 shows an inverse correlation with lung SCC progression; inhibition of Hugl-1 contributes to the progression of lung squamous cell carcinoma [13] . USP7 overexpression may regulate the survival and invasive properties of lung SCC and predict a poor prognosis of lung SCC [14] . Inhibition of the tumor-suppressive miR-29 family enhances cell invasion in lung SCC through direct regulation of oncogenic LOXL2 [15] . PRDM5 is a tumor suppressor frequently downregulated in tumors. DNA methylation of PRDM5 promoter contributes to the development of lung SCC [16] .
Transcription factors function by regulating gene expression through binding to specific DNA sequences and play essential roles in cancer cell processes, including cell proliferation, apoptosis, and migration. Downregulation of transcription factor PROX1 in esophageal squamous cell carcinoma (ESCC) inhibits cellular proliferation and migration; high expression of PROX1 in ESCC could be used as an indicator of poor prognosis [17] . FOXP3 inhibition decreases cell proliferation, migration, invasion, and the secretion of inhibitory cytokines in lung AC [18] .
In this study, we used bioinformatics methods to integrate mRNA expression data of lung SCC patients (which were available on the GEO database) in order to identify DEG differences between lung SCC and normal controls. We constructed a transcription factor gene regulatory network of DEGs in lung SCC to find the key transcription factors in lung SCC. The aim of this study was to provide valuable information for further elucidation of the mechanism of pathogenesis and to identify potential therapeutic targets for lung SCC.
Material and Methods

Microarray data
The Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih. gov/geo/) database was retrieved in order to obtain the microarray data of lung SCC (up to January 1, 2015) . The datasets including more than six lung SCC cases or controls. The inclusion criteria of datasets were set as follows: 1) the wholegenome expression profiling of lung SCC tissues or normal control tissues was available in the datasets; and 2) patients did not have preoperative treatment before collection of tumor tissues and normal controls. A total of six mRNA expression datasets of lung SCC were used in our study. Two datasets were based on a platform of GPL6480 Agilent-014850 Whole Human Genome Microarray 4x44K; other datasets were based on platforms of GPL10558 Illumina HumanHT-12 V4.0 expression beadchip, GPL6947 Illumina HumanHT-12 V3.0 expression beadchip, GPL9053 Agilent-UNC-custom-4X44K, and GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array.
Data preprocessing
Different sequencing platforms are known to commonly cause heterogeneity among different microarray datasets, which makes it difficult to compare microarray datasets directly. To eliminate these discrepancies, the raw expression datasets were downloaded and preprocessed, and background correction and normalization was performed using R package meta-MA [19] . For each gene, the expression level was calculated.
Identification of DEGs
The linear model limma [20] package for microarray data in R language was used to analyze the chip data. A t-test was used to identify genes expressed differently between lung SCC tumor samples and normal tissues samples. The p value and fold change were calculated. The p values from multiple studies were combined using Fisher's combined probability method. The false discovery rate (FDR) [21] was used for multiple test corrections of raw p values using the Benjamini and Hochberg method [22] . The threshold for the DEGs was set as FDR <0.01.
Hierarchical clustering
Hierarchical clustering has been extensively applied to identify groups of similarly expressed genes from gene expression data. To reveal samples in which the closest groups were adjacent, a two-way hierarchical clustering analysis [23] was applied to genes using the "pheatmap" package in R language. The results were displayed using a heat map.
GO and KEGG pathway enrichment analysis of DEGs
GO analysis has commonly been used for functional studies of large-scale transcriptomics data. The KEGG pathway database contains information of gene networks [24] . GOrilla was used for GO analysis and the Database for Annotation Visualization and Integrated Discovery (DAVID) [25] was used for KEGG pathway enrichment of DEGs. The threshold of GO function and KEGG pathway of DEGs was set as p<0.001 and FDR <0.01, respectively.
Identification of transcription factors and targeted genes
TRANSFAC (http://www.gene-regulation.com/pub/databases. html) [26] provides data on eukaryotic transcription factors, and includes experimentally-proven binding sites and consensus binding sequences. Data of Position Weight Matrix (PMW), human transcription factors, and binding sites motif of transcription factors were downloaded from TRANSFAC. Based on the downloaded data, DEGs were used for screening transcription factors and obtaining transcription factor regulated genes.
Construction of transcription factor regulatory network
The identified transcription factors and target genes were used for regulatory network construction, and the network was visualized by Cytoscape software (http://cytoscape.org/) [27] .
In this system, nodes represent transcription factors or target genes, and lines represent associations between transcription factors and target genes.
Results
Differentially expressed genes in lung SCC
We collected six mRNA expression profiles (GSE60644, GSE40588, GSE33479, GSE23822, GSE17710, and GSE10245), including 167 lung SCC cases and 99 normal controls (Table 1) . After normalization of the raw microarray data, 1,011 significant DEGs were identified in lung SCC compared to normal controls, including 549 upregulated and 462 downregulated genes based on the cut-off criteria. The top 15 significantly upregulated and downregulated genes are listed in Table 2 . The full list of DEGs are shown in Supplementary Table 1 . The expression pattern of the top 200 significant DEGs are displayed in Figure 1 .
GO annotation of DEGs in lung SCC
DEGs of lung SCC were performed uisng GO annotation to ascertain their biological roles. The threshold of GO terms was a p value <0.001. Vesicle-mediated transport (GO: 0016192, p=2.69×10 -12 ), regulation of multicellular organismal process (GO: 0051239, p=9.39×10 -10 ) and regulation of cell migration (GO: 0030334, p=2.25×10 -9 ) were the most significant enrichments of biological process. Molecular transducer activity (GO: 0060089, p=1.66×10 -13 ), receptor activity (GO: 0004872, p=1.67×10 -12 ) and signal transducer activity (GO: 0004871, p=1.49×10 -11 ) were the highest for enrichment of molecular function. Membrane part (GO: 0044425, p=3.30×10 -27 ), intrinsic component of membrane (GO: 0031224, p=1.76×10 -21 ), and integral component of membrane (GO: 0016021, p=4.01×10 -20 ) GEO Table 2 . Differentially expressed genes in lung SCC.
FC -fold change; FDR -false discovery rate; lung SCC -lung squamous cell carcinoma.
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were the highest for enrichment of cellular components, as shown in Table 3 .
KEGG pathway enrichment of DEGs in lung SCC
To obtain the signaling pathways of DEGs in lung SCC, the KEGG pathways were enriched for DEGs in lung SCC through DAVID. ), as shown in Table 4 . There were 38, 14, 13, 23, and 12 DEGs enriched in cell cycle, DNA replication, p53 signaling pathway, pathways in cancer, and cell adhesion molecules, respectively. FDR -false discovery rate; lung SCC -lung squamous cell carcinoma.
Construction of transcription factor gene regulatory network
Based on the TRANSFAC database, a total of 57 transcription factors and corresponding target genes were identified in the lung SCC-associated DEGs, including 20 upregulated transcription factors and 37 downregulated transcription factors. The 57 transcription factors and target genes were used to construct a regulatory network using Cytoscape software, as shown in Figure 2 
Discussion
In our study, NFIC regulated 83 DEGs and had the highest connectivity with DEGs in lung SCC. The expression level of NFIC was significantly downregulated in lung SCC compared to normal controls. NFIC regulated three of the top 15 upregulated genes, including GNGT1, DLX6, and PITX2 (Supplementary  Table 2 , Figure 2 ). NFIC has been shown to encode nuclear factor I/C, which belongs to the CTF/NF-I family. It has been reported that NFIC is associated with the tumor genesis of breast cancer, gastric cancer, and glioma [28] [29] [30] . NFIC is downregulated in invasive and noninvasive breast cancer cells compared to normal breast epithelial cells. Over-expression of NFIC induces expression of E-cadherin and KLF4 in breast cancer, which maintains epithelial differentiation status, leads to inhibition of EMT, and migration and invasion in breast cancer cells [30] . Recent reports suggest NFIC is dysregulated in gastric cancer. The NFI family has been shown to regulate the expression of B-FABP and GFAP, and results in increases in cell migration and anaplasia in malignant glioma cells [28] . NFIC has not previously been reported to be related to lung SCC. In our study, NFIC was a key transcription factor in the regulatory network (Figure 2 ), which indicates that NFIC might contribute to the pathogenesis of lung SCC. The biological function of NFIC in lung SCC needs to be further elucidated.
In our study, BRCA1 had the second highest connectivity with DEGs, and it regulated 82 DEGs in the regulatory network (Supplementary Table 2 , Figure 2 ). BRCA1 was significantly upregulated in lung SCC compared to normal controls. BRCA1 is known to encode the breast cancer 1 gene and act as a tumor suppressor. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and 80% of inherited ovarian cancers [31] . Mounting evidence shows that the expression of BRCA1 is associated with the natural prognosis and treatment prognosis in lung cancer [32, 33] . High levels of BRCA1 and SETDB1 expression have been significantly associated with shorter disease-free survival in stage I NSCLC patients [33] . NSCLC patients lacking the expression of ERCC1 and BRCA1 benefit more from adjuvant cisplatin-based chemotherapy compared with patients that expressed either ERCC1 or BRCA1 [32] . All of the aforementioned suggests that BRCA1 might play a vital role in cell proliferation, motility, and invasion of NSCLC.
In our study, NFATC2 regulated 75 DEGs in the regulatory network (Supplementary Table 2 , Figure 2 ) and had the third highest connectivity with DEGs. NFATC2 was downregulated in lung SCC compared to normal controls. The second top upregulated gene (Table 2) , HOXD13, was regulated by NFATC2. NFATC2 is known to encode the nuclear factor of activated T-cells, cytoplasmic, and calcineurin-dependent 2, which is a member of the nuclear factor of activated T cells family. NFATC2 is considered to be involved in the development of cardiac, skeletal muscle, nervous system, and tumor genesis. NFATC2 contributes to the development of breast cancer, colon cancer, and lung cancer [34] [35] [36] [37] . In the experimental model, NFATC2-deficient mice with colitis were protected from colorectal carcinoma development, in contrast to wild-type BALB/c mice [34] .
Moreover, NFATC2 has been shown to promote the migration and invasion of breast cancer cells in vitro [36] . In breast cancer, NFATC2-mediated IL8 production promotes the migration of primary human neutrophils in vitro, and promotes neutrophil infiltration in tumor xenografts and suppresses tumor growth [37] . NFATC2 is known to be overexpressed in lung cancer, and depleting the expression of NFATC2 in NSCLC cells can inhibit cell invasion, migration, and metastasis. In our study, NFATC2 was downregulated in lung SCC, the biological functions of NFATC2 in the development of lung SCC were unclear, and the underlying mechanism of action needs further study.
A total of 1,011 DEGs were identified in lung SCC compared to normal controls. All of the DEGs were significantly enriched in several KEGG pathways, including cell cycle, DNA replication, p53 signaling pathway, pathways in cancer, adherens junction, and cell adhesion molecules (Table 4) . It has been previously reported that cell cycle and DNA replication is significantly enriched in lung SCC [38] , which is accordance with our analysis.
Conclusions
We identified 1,011 DEGs, including 549 upregulated genes and 462 downregulated genes, in lung SCC. Transcription factors of lung SCC were identified and assays performed to construct a transcription factor regulatory network. In this network, we found several transcription factors, including NFIC, BRCA1, and NFATC2, which may play important roles in lung SCC via cell cycle and DNA replication signaling pathways. Our findings might provide valuable information for additional pathogenesis elucidation of lung SCC. Moreover, our study revealed that NFIC, BRCA1, and NFATC2 might be clinically useful if tested further for their therapeutic value.
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